Literature DB >> 17890871

Frusemide administration in critically ill patients by continuous compared to bolus therapy.

Marlies Ostermann1, George Alvarez, Michael D Sharpe, Claudio M Martin.   

Abstract

BACKGROUND: Frusemide is frequently administered to critically ill patients in the intensive care unit (ICU). We investigated whether continuous frusemide infusion therapy was more effective than regular intermittent bolus doses at causing diuresis.
METHODS: 59 adult patients with fluid overload admitted to two tertiary multidisciplinary ICUs were randomised to either a continuous frusemide infusion or regular intermittent intravenous boluses of frusemide according to pre-defined algorithms aiming for a minimum hourly urine output.
RESULTS: There was no significant difference in diuretic response between the two groups during the first 24 h (5.3 liters in the bolus group vs. 5.4 liters in the infusion group). In the bolus group a significantly higher dose of frusemide was needed to achieve target diuresis (24.1 vs. 9.2 mg/h in the infusion group, p = 0.0002). Mean urine output per dose of frusemide was significantly higher in the infusion group (31.6 vs. 18 ml/mg in the bolus group, p = 0.014). At the end of the study, there were no differences in hospital mortality, number of patients requiring ventilatory support, change in serum creatinine or change in estimated glomerular filtration rate.
CONCLUSIONS: Both intermittent boluses and continuous infusion of frusemide were successful in achieving algorithm-driven diuresis. However, continuous infusion therapy was more effective than intermittent boluses since the dose of frusemide required was significantly less. (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17890871     DOI: 10.1159/000108641

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  8 in total

1.  Continuous versus bolus dosing of Furosemide for patients hospitalized for heart failure.

Authors:  Larry A Allen; Aslan T Turer; Tracy Dewald; Wendy Gattis Stough; Gadi Cotter; Christopher M O'Connor
Journal:  Am J Cardiol       Date:  2010-04-27       Impact factor: 2.778

Review 2.  Fluid and electrolyte overload in critically ill patients: An overview.

Authors:  Bruno Adler Maccagnan Pinheiro Besen; André Luiz Nunes Gobatto; Lívia Maria Garcia Melro; Alexandre Toledo Maciel; Marcelo Park
Journal:  World J Crit Care Med       Date:  2015-05-04

Review 3.  Furosemide as a functional marker of acute kidney injury in ICU patients: a new role for an old drug.

Authors:  Filippo Mariano; Alberto Mella; Marco Vincenti; Luigi Biancone
Journal:  J Nephrol       Date:  2019-05-14       Impact factor: 3.902

4.  The SPARK Study: a phase II randomized blinded controlled trial of the effect of furosemide in critically ill patients with early acute kidney injury.

Authors:  Sean M Bagshaw; R T Noel Gibney; Finlay A McAlister; Rinaldo Bellomo
Journal:  Trials       Date:  2010-05-11       Impact factor: 2.279

5.  Defining fluid removal in the intensive care unit: A national and international survey of critical care practice.

Authors:  Michael E O'Connor; Sarah L Jones; Neil J Glassford; Rinaldo Bellomo; John R Prowle
Journal:  J Intensive Care Soc       Date:  2017-06-13

6.  Continuous versus intermittent use of furosemide in patients with heart failure and moderate chronic renal dysfunction.

Authors:  Zhigui Zheng; Xinxin Jiang; Jianguo Chen; Dongyuan He; Xiaohui Xie; Yunan Lu
Journal:  ESC Heart Fail       Date:  2021-03-10

7.  Intermittent furosemide administration in patients with or at risk for acute kidney injury: Meta-analysis of randomized trials.

Authors:  Tiziana Bove; Alessandro Belletti; Alessandro Putzu; Simone Pappacena; Giuseppe Denaro; Giovanni Landoni; Sean M Bagshaw; Alberto Zangrillo
Journal:  PLoS One       Date:  2018-04-24       Impact factor: 3.240

8.  Impact of protocolized diuresis for de-resuscitation in the intensive care unit.

Authors:  Brittany D Bissell; Melanie E Laine; Melissa L Thompson Bastin; Alexander H Flannery; Andrew Kelly; Jeremy Riser; Javier A Neyra; Jordan Potter; Peter E Morris
Journal:  Crit Care       Date:  2020-02-28       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.